Being able to quickly and cost-effectively collect, analyze and share real-world evidence on a treatment is critical for product launch and post-market success.
Real-world research in the context of big data, emerging AI technologies, and linked registries offers new opportunities for accessing important outcomes and using them to demonstrate comparative effectiveness and deliver value and benefit messages.
Join OM1’s Dr. Richard Gliklich and Kathryn Starzyk as they explore using real-world data for:
- Evaluating DMARD treatment patterns, therapy switching, and disease activity;
- Understanding comparative performance;
- Monitoring outcomes of interest and predicting which patients are most at risk; and
- Demonstrating product value based on outcomes.